Literature DB >> 4027929

Cell kinetics as a prognostic marker in node-negative breast cancer.

R Silvestrini, M G Daidone, G Gasparini.   

Abstract

The relevance of cell kinetics of the primary tumor as a marker of biologic aggressivity was verified on a series of 258 patients with operable breast cancer without nodal and distant metastases, who underwent radical mastectomy without any other treatment until relapse. The cell proliferative rate, evaluated in vitro on fresh tumor material and expressed as 3H-thymidine labeling index, was found to be an important discriminant of metastatic potential. Patients with slowly proliferating tumors showed a higher probability of 6-year relapse-free survival in comparison to those with fast-proliferating tumors (80.5% versus 59.6%, P = 0.00004). This finding was true for premenopausal and paramenopausal (P = 0.00005) as well as for postmenopausal patients (P = 0.01). The kinetic variable was also a discriminant of 6-year survival for the overall series (P = 0.003) and for premenopausal and paramenopausal patients (P = 0.003) regardless of the type of treatment after relapse. These findings show the relevance of the kinetic variable as an important prognostic marker in breast cancer.

Entities:  

Mesh:

Year:  1985        PMID: 4027929     DOI: 10.1002/1097-0142(19851015)56:8<1982::aid-cncr2820560816>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activity in vitro: experience on 136 primary cancers and on 116 recurrences.

Authors:  W Zoli; A Volpi; C Bonaguri; A Riccobon; S Savini; R Brizio; A Saragoni; L Medri; G A Marra; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

2.  Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer.

Authors:  G Gasparini; S Meli; G A Panizzoni; A Visonà; P Boracchi; P Bevilacqua; E Marubini; F Pozza
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

3.  Prognostic value of morphometry in breast cancer.

Authors:  J P Baak; J C van der Linden; P J van Diest
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

4.  Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence.

Authors:  T Hatschek; O Gröntoft; G Fagerberg; O Stål; S Sullivan; J Carstensen; B Nordenskjöld
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

5.  Interpretation of the risk associated with the unexpected finding of lobular carcinoma in situ.

Authors:  S Zurrida; C Bartoli; V Galimberti; R Raselli; L Barletta
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

6.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

7.  Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay.

Authors:  M G Daidone; R Silvestrini; N Zaffaroni; E Grignolio; F Landoni
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

8.  Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.

Authors:  J S Meyer; M Province
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

9.  Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.

Authors:  H Kreipe; P Alm; H Olsson; M Hauberg; L Fischer; R Parwaresch
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

Review 10.  Current management of carcinoma of the breast.

Authors:  T J Eberlein
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.